Search clinical trials for: folfoxiri

Total 89 results

AIPING ZHOU

Completed

Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Gruppo Oncologico Italiano di Ricerca Clinica

Unknown

Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR)

Colorectal Cancer

Italy
Sun Yat-sen University

Completed

FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (FOCULM)

Metastatic Colorectal Cancer

China
Gruppo Oncologico del Nord-Ovest

Unknown

Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2)

Metastatic Colorectal Cancer

Italy
Chugai Pharmaceutical

Unknown

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC (QUATTRO-II)

Metastatic Colorectal Cancer

Japan
Technische Universität Dresden

Unknown

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases (CELIM2)

Colorectal Cancer

Germany
Guangxi Medical University

Withdrawn

FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer

Rectal Cancer

China
Hasselt University
Ziekenhuis Oost-Limburg

Terminated

Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure (DIPSTICK)

Heart Failure

Belgium
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (VISNU-1)

Metastatic Colorectal Cancer

Spain
National Cheng-Kung University Hospital

Unknown

The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases (CBL)

Colorectal Cancer

Taiwan
Hanoi Medical University

Completed

Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI

Colorectal Cancer

Vietnam
Fujian Cancer Hospital

Withdrawn

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Metastatic Colorectal Cancer

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (TRUST)

Rectal Cancer

Italy
RenJi Hospital

Active, not recruiting

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Rectal Cancer Stage III

China
RenJi Hospital

Unknown

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Rectal Cancer

China
Hoffmann-La Roche

Terminated

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (STEAM)

Colorectal Neoplasms

United States
Spanish Cooperative Group for the Treatment of...
Bayer

Terminated

Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (PREVIUM)

Colorectal Neoplasms | Metastatic Disease

Spain
EPS Corporation

Completed

A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC (QUATTRO)

Colorectal Neoplasms

Japan
Hoffmann-La Roche

Completed

OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer

Colorectal Cancer

Germany
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

France, Spain, Austria, United Kingdom
The First Affiliated Hospital of Zhengzhou University

Completed

Aminophylline for Patients With Post-Dural Puncture Headache

Post-dural Puncture Headache

China
Soroka University Medical Center

Withdrawn

Progesterone for First Trimester Vaginal Bleeding

Premature Birth | Pre-Eclampsia | Fetal Growth Retardation | Threatened Abortion | Abruptio Placentae

Israel
Sun Yat-sen University

Unknown

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type (FORBES)

Metastatic Colorectal Cancer

China
Medical University of Vienna

Unknown

Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer (CARCINOSIS)

Colorectal Cancer | Peritoneal Metastasis

Austria
PregLem SA

Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII)

Uterine Fibroids

Belgium, Poland, Austria, Spain
Centro Nacional de Investigaciones Oncologicas...
Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...

Completed

Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets

Advanced Pancreatic Carcinoma

Spain
University Hospital of Crete

Completed

Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

Metastatic Colorectal Cancer

Greece
Japan Clinical Cancer Research Organization

Unknown

A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab (DEEPER)

Colorectal Cancer
SCRI Development Innovations, LLC
Amgen

Completed

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Colorectal Cancer

United States
Gruppo Oncologico del Nord-Ovest

Completed

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (MACBETH)

Metastatic Colorectal Cancer

Italy
Gruppo Oncologico del Nord-Ovest

Completed

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
Gruppo Oncologico del Nord-Ovest

Completed

FOLFOXIRI Plus Panitumumab In Kras and Braf Wild-Type Metastatic Colorectal Cancer (TRIP)

Metastatic Colo-rectal Cancer

Italy
Gruppo Oncologico del Nord-Ovest

Completed

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer (FOIB)

Colorectal Cancer Metastatic
Azienda Ospedaliero, Universitaria Pisana

Unknown

Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer (GIP-2)

Pancreatic Cancer

Italy
Azienda Ospedaliero, Universitaria Pisana

Completed

FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer (FLAP)

Pancreatic Carcinoma Stage III

Italy
Sun Yat-sen University

Unknown

FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Soon Chun Hyang University

Unknown

Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Azienda Ospedaliero, Universitaria Pisana

Completed

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
National Center for Tumor Diseases, Heidelberg
Pfizer; Roche Pharma AG

Terminated

Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (APRIORI)

Colorectal Carcinoma

Germany

3

Subscribe